Volume 3.36 | Sep 11

Hematopoiesis News 3.36 September 11, 2012
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Scientists Discover ‘Missing Link’ between Blood Stem Cells, Immune System
Researchers have discovered a type of cell that is the “missing link” between bone marrow stem cells and all the cells of the human immune system, a finding that will lead to a greater understanding of how a healthy immune system is produced and how disease can lead to poor immune function. [Press release from the University of California, Los Angeles discussing online prepublication in Nature Immunology]
Press Release | Abstract

StemSpan ACF: The WORLD'S FIRST Plasma Component-Free Hematopoietic Expansion Media. Come learn more.
PUBLICATIONS (Ranked by impact factor of the journal)


FLT3-ITD Knockin Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to Myeloproliferative Neoplasm
Expression of FMS-like tyrosine kinase-3 (FLT3)-internal tandem duplication (ITD) from the endogenous promoter in a murine knockin model results in progenitor expansion and a myeloproliferative neoplasm. In this study, the authors showed that this expansion begins with overproliferation within a compartment of normally quiescent long-term hematopoietic stem cells, which become rapidly depleted. [Cell Stem Cell] Abstract

Temporal Changes in PTEN and mTORC2 Regulation of Hematopoietic Stem Cell Self-Renewal and Leukemia Suppression
Researchers showed that Rictor deletion prevents leukemogenesis and hematopoietic stem cell depletion after Pten deletion in adult mice, implicating mTORC2 activation in these processes. [Cell Stem Cell] Abstract

Cis-Element Mutated in GATA2-Dependent Immunodeficiency Governs Hematopoiesis and Vascular Integrity
GATA2 encodes a master regulator of hematopoiesis that is also linked to endothelial biology. Though the disease-causing mutations commonly occur in the GATA-2 DNA binding domain, scientists identified a patient with mycobacterial infection and myelodysplasia who had an uncharacterized heterozygous deletion in a GATA2 cis-element consisting of an E-box and a GATA motif. [J Clin Invest] Full Article | Press Release

PTH Expands Short-Term Murine Hemopoietic Stem Cells through T Cells
Scientists showed that T cells are required for intermittent parathyroid hormone (iPTH) to expand short-term hemopoietic stem and progenitor cells and improve blood cell engraftment and host survival after bone marrow transplantation. [Blood] Abstract

Targeting JAK1/2 and mTOR in Murine Xenograft Models of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (ALL)
Researchers investigated the efficacy of the JAK inhibitor ruxolitinib and the mTOR inhibitor rapamycin in xenograft models of eight pediatric B-precursor ALL cases with and without CRLF2 and JAK genomic lesions. [Blood] Abstract

C/EBPβ Promotes BCR-ABL-Mediated Myeloid Expansion and Leukemic Stem Cell Exhaustion
Investigators examined the role of C/EBPβ, a regulator for ′emergency granulopoiesis′, in the pathogenesis of the chronic phase of chronic myeloid leukemia. [Leukemia] Abstract

Sorafenib Has Potent Anti-Tumor Activity in Multiple Myeloma In Vitro, Ex Vivo and In Vivo, in the 5T33MM Mouse Model
Researchers demonstrated that sorafenib induces cell death in multiple myeloma (MM) cell lines and in CD138+ enriched primary MM patient samples in a caspase-dependent and independent manner. [Cancer Res] Abstract | Press Release

Multifaceted Roles of PTEN and TSC Orchestrate Growth and Differentiation of Drosophila Blood Progenitors
Investigators demonstrated that in the Drosophila lymph gland the tumor suppressors TSC and PTEN control blood progenitor proliferation through a common TOR- and 4EBP-dependent pathway. [Development] Abstract | Press Release


Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia
In childhood acute myeloid leukemia (AML), morphologic assessment of treatment response has limited value if minimal residual disease is measured by flow cytometry. MLL fusion transcripts can provide prognostic information in some patients, whereas monitoring of AML1-ETO and CBFβ-MYH11 transcripts is largely uninformative. [J Clin Oncol] Abstract | Press Release

Age-Adjusted Recipient Pre-Transplant Telomere Length and Treatment-Related Mortality after Hematopoietic Stem Cell Transplantation
Researchers concluded that age-adjusted recipients’ telomere length is an independent biological marker of treatment related mortality after hematopoietic stem cell transplantation. [Blood] Abstract

FREE Technical Resource: Atlas of Hematopoietic Colonies from Cord Blood. Request your copy.

Less Is More: Unveiling the Functional Core of Hematopoietic Stem Cells through Knockout Mice
Researchers propose recommendations for characterization of hematopoietic stem cell (HSC) function in knockout mice to facilitate cross-study comparisons that would generate a more cohesive picture of HSC biology. [Cell Stem Cell] Abstract

8th World Stem Cell Summit

$36.4 Million Funds for Radiation Syndrome Cell Therapy
Cellerant Therapeutics won a $36.4 million Biomedical Advanced Research and Development Authority grant to support advanced development of allogeneic cell-based therapy CLT-008, for the treatment of acute radiation syndrome. CLT-008 is an off-the-shelf cryopreserved cell-based therapy comprising human myeloid progenitor cells derived from hematopoietic stem cells. [Genetic Engineering & Biotechnology News]
Press Release

Sunesis Pharmaceuticals to Implement One-Time Sample Size Increase to Phase III VALOR Trial in AML
Sunesis Pharmaceuticals, Inc. announced that it will implement a one-time, 225-patient sample size increase to its Phase III VALOR trial of vosaroxin in acute myeloid leukemia (AML), bringing target enrollment to 675 patients. [Sunesis Pharmaceuticals, Inc.] Press Release

Third Critically Ill Patient Successfully Treated with Pluristem’s PLX Cells under Compassionate Use
Pluristem Therapeutics, Inc. announced that the Company’s Placental eXpanded (PLX) cells were successfully administered to a third patient in Hadassah Medical Center; thus, a series of three life saving compassionate use treatments were completed. [Pluristem Therapeutics, Inc.] Press Release

BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers
BioLineRx Ltd. announced that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd. for the development and commercialization of BL-8040, a Phase II ready drug candidate for the treatment of acute myeloid leukemia, as well as other types of hematological cancer. [BioLineRx Ltd.] Press Release

U.S. Food and Drug Administration Approves BOSULIF® (bosutinib) for Patients with Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML)
Pfizer Inc. announced the U.S. Food and Drug Administration has approved BOSULIF® for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive CML with resistance, or intolerance to prior therapy. [Pfizer Inc.] Press Release

STEMSOFT Welcomes New EMEA Sales Director
STEMSOFT Software Inc (“STEMSOFT”), the leading provider of software solutions for the cell therapy and transplant community, is pleased to welcome Isabel Feys on board as the new Director of Sales for the EMEA area. [STEMSOFT Software Inc] Press Release


Obama and Romney Tackle 14 Top Science Questions
Scientific American partnered with grassroots organization ScienceDebate.org to encourage the two main presidential candidates – Barack Obama and Mitt Romney – to answer 14 questions on some of the biggest scientific and technological challenges facing the nation. [Presidential Candidates, United States]
Press Release

U.K. Devotes £10 Million to Open Access Shift
Following up on recommendations to make more research freely available to scientists and the public, the U.K. government pledged £10 million toward making scientific papers open access. [U.K. Government, United Kingdom] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW The Jackson Laboratory: The Power of Modeling Human Disease in NSG Mice
September 13, 1:00PM (ET in US)

NEW 9th Stem Cell Research & Therapeutics Conference
October 24-26, 2012
Philadelphia, United States

Visit our events page to see a complete list of events in the hematopoietic community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications and Publishing Coordinator (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Postdoctoral Position(s) – Pharmaceutical Immunology/Hematopoietic Cell Development (National Taiwan University)

Research Associate – Quality Assurance (University of California)

Postdoctoral Position – Mouse Stem Cell Biology (University of Alabama)

Postdoctoral Position – Stem Cells and Cancer (Tsinghua University)

Scientist, Postdoctoral and Research Associate Positions (University of Miami – Sylvester Comprehensive Cancer Center)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us